Bladder cancer

  title={Bladder cancer},
  author={A. Kamat and N. Hahn and J. Efstathiou and S. Lerner and W. Kassouf},
  journal={The Lancet},
  • A. Kamat, N. Hahn, +2 authors W. Kassouf
  • Published 2016
  • Medicine
  • The Lancet
  • Bladder cancer is a complex disease associated with high morbidity and mortality rates if not treated optimally. Awareness of haematuria as the major presenting symptom is paramount, and early diagnosis with individualised treatment and follow-up is the key to a successful outcome. For non-muscle-invasive bladder cancer, the mainstay of treatment is complete resection of the tumour followed by induction and maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy… CONTINUE READING
    49 Citations

    Paper Mentions

    Interventional Clinical Trial
    Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2… Expand
    ConditionsBladder Carcinoma
    Management of Muscle‐Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer
    • 14
    • Highly Influenced
    Predicting Disease Course in Bladder Cancer: STAG2 as a Prognostic Biomarker
    Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population
    • 2
    Targeting advanced urothelial carcinoma-developing strategies
    • 3
    A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
    • 192
    • PDF


    The clinical significance of molecular markers to bladder cancer.
    • 22
    Molecular prognostic factors in bladder cancer
    • 17
    • PDF
    The role of Ras superfamily proteins in bladder cancer progression.
    • 87
    Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer
    • 121